Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 9/20 | 0.40 |
| ▸ | TACR1 | P25103 | 9/20 | 0.40 |
| ▸ | TAC3 | Q9UHF0 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 9/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931113 | 1.00 | TACR2 (0.40) | TACR2TACR1TAC3ALDH1A1MAPT | |
| SCHEMBL2797617 | 1.00 | TACR2 (0.40) | TACR2TACR1TAC3ALDH1A1MAPT | |
| SCHEMBL1937992 | 0.89 | TACR2 (0.39) | TACR2TACR1TAC3ALDH1A1TACR3 | |
| SCHEMBL7934979 | 0.89 | TACR2 (0.39) | TACR2TACR1TAC3ALDH1A1TACR3 | |
| SCHEMBL2799901 | 0.89 | TACR2 (0.39) | TACR2TACR1TAC3ALDH1A1TACR3 | |
| SCHEMBL7934200 | 0.89 | TACR3 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL2796395 | 0.89 | TACR1 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL7931924 | 0.89 | TACR1 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL2800494 | 0.89 | TACR3 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL1935480 | 0.89 | TACR3 (0.43) | TACR2TACR1TAC3TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293770-B2 | Pyrrolidine derivatives as NK-3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2331500-A1 | PYRROLIDINE N-BENZYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100168088-A1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010040663-A1 | PYRROLIDINE N-BENZYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168088-A1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | OPRK1, OPRL1, OPRD1 | TACR2 10/4885TACR1 8/4885TAC3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.